Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotuletinib +/- Spartalizumab in Advanced Solid Tumors
NCT02829723Phase 2Terminated
- Sponsor
- Novartis
- Start
- Oct 2016
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, open-label trial of sotuletinib in solid tumor (advanced stage), glioblastoma (GBM) and Hodgkin lymphoma (HL) (2 arms), sponsored by Novartis. Primary endpoints: Adverse Events, Dose Reductions and Interruptions and 3 more. Started Oct 2016; status: terminated.
02
Drugs
sotuletinib
03
Conditions
solid tumor (advanced stage)glioblastoma (GBM)Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT02829723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02829723.